Ceribell Inc's Business Segments

Founded in 2014, the company develops and sells the Ceribell System, which includes headbands, recorders, and a portal. These medical devices have received FDA clearance. Commercial sales began in 2018, and by the end of 2025, the company employed over 300 people. Its operations focus on the development, manufacturing, and commercialization of the Ceribell System and related algorithms, primarily for use in acute care settings as an alternative to conventional EEG systems. The company has experienced challenges related to rapid growth, including scaling operations, recruiting skilled personnel, expanding manufacturing capabilities, and managing regulatory compliance. Since inception, the company has incurred net losses, reporting a net loss of $53.4 million in 2025 and an accumulated deficit of $220.4 million. Revenue is mainly generated from sales of the Ceribell System. Future performance depends on market acceptance, customer acquisition, and retention. The company invests in marketing and brand-building to increase product awareness and adoption. Operational risks include fluctuations in financial results, potential delays in onboarding new accounts, and managing increased expenses and infrastructure demands associated with business expansion. The company anticipates continued growth and related costs but does not guarantee profitability or sustained growth.